BioSpace News Archive

Funding to drive investigation of further potential indications for lead product candidate, KarXT First U.S. Patent awarded for KarXT

MD Anderson Phase II trial shows drug well tolerated with high response rates for marginal zone lymphoma

Assertio Therapeutics, Inc. announced today that James J. Galeota, Jr. has been appointed to the Company’s Board of Directors.

The investigational therapeutic umbralisib, which targets the molecule PI3K- delta, was well tolerated and highly active in patients with relapsed/refractory marginal zone lymphoma, according to early results from the UNITY-NHL phase II clinical trial, which were presented at the AACR Annual Meeting 2019, March 29–April 3.

NOXXON Pharma N.V. announced the latest update of clinical results from the Phase 1/2 study of NOX-A12 in combination with Keytruda® in patients with microsatellite-stable, metastatic pancreatic and colorectal cancer in a poster presentation at the American Association for Cancer Research Annual Meeting.

Study 3 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant

During a presentation at the American Association for Cancer Research meeting over the weekend, Astellas touted new overall survival data for Xospata.

Novartis will pay $310 million upfront for the Boston-based inflammation company IFM Tre. IFM TRE is very much an early-stage company, with one compound, IFM-2427, in an early Phase I clinical trial, and two preclinical assets.

The American Association for Cancer Research (AACR) Annual Meeting is ongoing in Atlanta, with plenty of companies presenting interesting and cutting-edge science. Here’s a look at just a representative few.

The lynchpin to biotech and pharmaceutical drug development in the United States is arguably the greater Boston area, which includes the white hot square mile of talent and intellectual collaboration found in Kendall Square.